Article

Optimal control strategy for the effectiveness of TB treatment taking into account the influence of HIV/AIDS and diabetes

Erick Manuel Delgado Moya\textsuperscript{1,*}, Alain Pietrus\textsuperscript{2} and Sergio Muniz Oliva Filho\textsuperscript{1}

\textsuperscript{1} Institute of Mathematics and Statistics, Department of Applied Mathematics, University of Sao Paulo, Brazil.

\textsuperscript{2} University of Antilles, Department of Mathematics and Computer Sciences, LAMIA (EA 4540), BP 250, 97159, Pointe-a-Pitre, Guadeloupe, France.

* Correspondence: erickmath@ime.usp.br

Abstract: The aim of this paper is to present an optimal control problem to reduce the MDR-TB (multidrug-resistant tuberculosis) and XDR-TB (extensively drug-resistant TB) cases, using controls in these compartments and controlling reinfection/reactivation of the bacteria. The model used studies the efficacy of the tuberculosis treatment taking into account the influence of HIV/AIDS and diabetes, and we prove the global stability of the disease-free equilibrium point based on the behavior of the basic reproduction number. Various control strategies are proposed with the combinations of controls. We show the existence of optimal control using Pontryagin’s maximum principle. We solve the optimality system numerically with an algorithm based on forward/backward Runge-Kutta method of the fourth-order. The numerical results indicate that the implementation of the strategy that activates all controls and of type I (starting with the highest controls) is the most cost-effective of the strategies studied. This strategy reduces significantly the number of MDR-TB and XDR-TB cases in all sub-populations, which is an important factor in combating tuberculosis and its resistant strains.

Keywords: Optimal control; Diabetes; HIV/AIDS; ordinary differential equations; Tuberculosis.

MSC: 49J15; 92D30; 62P10.

1. Introduction

Tuberculosis is a chronic bacterial infectious disease caused by "\textit{Mycobacterium Tuberculosis}". The main medical problems faced is the effectiveness of anti-TB treatments and extensively drug-resistant TB (XDR-TB) cause alarm of future non-effective TB drugs [1].

The number of cases of tuberculosis in the world has been increasing annually. For example in 2015, 10.4 million new cases were estimated in the world, 1.4 million TB-induced deaths, and 0.4 million deaths resulting from TB-HIV/AIDS co-infection [2].

The rifampcin, isoniazid, pyrazinamide, ethambtol are some of the first-line drugs for TB treatment and amikacin, capriomycin, cycloserine, azithromycin, clavithromycin, moxifloxacin, levofloxacin are the second line of treatment.

The treatment applied for active forms of tuberculosis is using first-line drugs (rifampcin, isoniazid, pyrazinamide, ethambtol) which belong to the first line of treatment for 4 months and followed by a daily intake of rifampcin and isoniazid for a period of four months.

Multidrug-resistant tuberculosis (MDR-TB) is caused by Mycobacterium tuberculosis strains with resistance to at least isoniazid and rifampin. Extensively drug-resistant tuberculosis (XDR-TB) is defined as a strain resistant to any type of fluoroquinolone and mainly to one of three injectable drugs: amikacin, capreomycin, or kanamycin in addition to isoniazid and rifampin [3]. According to Gandhi \textit{et al.}, [4], about 3.2% of all new tuberculosis cases are multidrug-resistant (MDR-TB).

Diabetes is a risk factor for lower respiratory infections including TB and is a significant factor for TB infections at the population level [5]. Stevenson \textit{et al.}, reported that diabetes increases TB risk 1.5 to 7.8 times [6] and Jeon and Murray found that the relative risk for TB among diabetes patients was 3.11 [7]. Diabetes can
affect the effectiveness of anti-TB drugs, especially rifampicin, by reducing their plasma concentrations [8]. Currently, the treatment regimen for diabetics and non-diabetics is the same [5].

TB can lead to impaired glucose tolerance (IGT) and new-onset diabetes [9]. In general, IGT normalizes once recovered from TB but remains an important risk factor for the future development of type 2 diabetes.

The rate of diabetes for HIV patients when they are infected is the same as for the general population. But certain metabolic factors related to HIV, and HIV therapy can increase the incidence of diabetes over 5 time. Cases of diabetes in HIV patients on antiretroviral therapy have been increasing. This problem appears to be related to the use of protease inhibitors and one of the solutions is the discontinuation of therapy. Patients on treatment for HIV should be monitored and consider to changes in therapy or specific treatment when metabolic problems occur.

Recurrent tuberculosis disease can occur as a result of reinfection, in which a patient becomes exogenously infected with a strain of Mycobacterium tuberculosis other than the organism that caused the original infection. A caveat in this regard is that, in high-incidence settings, patients, on rare occasions, may be exposed to or infected with a very similar or the same strain as in the primary infection, making it difficult to differentiate between relapse and reinfection in these particular cases [10]. Reinfection or reactivation is linked to the immune status of the patient and takes into account the behavior of the prevalence of the disease; in the case of HIV, the higher the prevalence, the higher the incidence of TB. Several studies have now shown that multiple genotypes can be detected by sampling both respiratory and extrapulmonary sites in seropositive individuals, illustrating the presence of migration routes within and between organs [11]. Reactivation TB may occur if the patient’s immune system is weakened and cannot contain the latent bacteria. The bacteria then become active; they overload the immune system and cause the person to become ill with tuberculosis.

Optimal control theory has been used for studying the transmission dynamic of TB in [12–16]. Example, Kim et al., [12] proposed optimal control strategies to reduce the number of patients at high risk for latent and infectious tuberculosis with minimal intervention costs. Numerical simulation with data from the Philippines showed that distancing control is the most efficient control strategy when a single intervention is performed. Silva and Torres [13] applied optimal control theory using the prevention of exogenous reinfection as control in a tuberculosis disease. Jung et al., [14] applied optimal control theory to a two-strain tuberculosis model with aim to reduce the latent and infectious groups with the resistant-strain tuberculosis, where the controls are two types of treatments. Silva and Torres [16] applied optimal control theory to minimize the cost of interventions in a model of tuberculosis with reinfection and exposure.

The problems of HIV/AIDS control and TB-HIV/AIDS co-infection with different techniques have become a problem approached by researchers in last time. For example, Tahir et al., [17] extended a mathematical model of TB-HIV/AIDS co-infection to study the optimal control problem, and defined different schemes to minimize and control infection in any population. Awoke and Kassa [18] presented and studied a mathematical model for a transmission of TB-HIV/AIDS co-infection that incorporates prevalence dependent behaviour change in the population and treatment for the infected and applied optimal control theory to minimize the cost of infections and control enforcement efforts.

We can find applications of the optimal control theory in the study of TB-HIV/AIDS co-infection in [19–22]. Agusto and Adekunle [19] used optimal control theory to investigate optimal control strategies in disease spread and demonstrated that the combined strategy of preventing treatment failure in TB-infected individuals and treating individuals with drug-resistant TB is the most cost-effective. Silva and Torres [20] formulated a population model for TB-HIV/AIDS co-infection that considers antiretroviral therapy for HIV infection and treatments for latent and active TB, and used the theory of optimal control to reduce the number of individuals with active TB and AIDS. Fatmawati and Tasman [21] presented an optimal control problem on the treatment of the transmission of TB-HIV co-infection model, using anti-TB and antiretroviral treatments as controls. Tanvi and Aggarwal [22] presented an HIV/AIDS and TB co-infection model and proposed an optimal control problem to minimize the cost of the detection and treatment.

The study of diabetes control and its relationship to TB has increased in recent decades. For example, Kouidere et al., [23] proposed conducting awareness campaigns based on the severity of complications of diabetes, the importance of a balanced lifestyle, and correct use of treatment as an optimal control strategy. Chávez et al., [24] formulated a control system for optimal insulin delivery in type I diabetic patients using the linear and quadratic control problem theory. The linear model is used for the glucose-insulin dynamics and the non-linear for the evaluation of the regulatory controller.

The objective of this work is to present and solve the optimal control problem to reduce the resistance to tuberculosis treatment, taking into account the influence of HIV/AIDS and diabetes.
This paper is organized as follows: §2 briefly describes a mathematical model for the study of resistance to treatment of tuberculosis in the presence of HIV/AIDS and diabetes presented in [25]. In §3 is incorporated four controls in order to reduce the impact of TB treatment resistance and we study the optimal control problem. §4 includes numerical experimentation and §5 is about some conclusions.

2. Model formulation

In this section, we present the model with ordinary differential equations introduced in [25] and its basic properties. This model is designed for the study of MDR-TB and XDR-TB, taking into account the influence of HIV/AIDS and diabetes.

The model compartments are: uninfected of TB, \((S_T, S_H, S_D)\), latently infected, \((E_T, E_H, E_D)\), individuals infected and drug-sensitive to TB \((I\_T, I\_H, I\_D)\), MDR-TB infected \((I\_T, I\_H, I\_D)\), XDR-TB infected \((R\_T, R\_H, R\_D)\) and recovered of TB \((R_T, R_H, R_D)\) individuals where \(T\) represent TB-Only individuals, \(H\) are HIV/AIDS cases and \(D\) diabetics.

The \(M_1, M_2\) and \(M_3\) are recruitment rates only-infected-TB, HIV/AIDS and diabetes respectively. The rate of acquiring diabetes by use of antiretroviral treatment is \(d_1\) and the rate of an individual acquiring HIV and of developing diabetes are \(d_2\) and \(d_3\) respectively.

The TB infection rate is defined as

\[
\lambda_T = \alpha^* \frac{I\_T + I\_D + R\_T + \epsilon_1(I\_H + I\_H + R\_H) + \epsilon_2(I\_D + I\_D + R\_D)}{N}
\]

where \(\alpha^*\) is the effective contact rate and \(N\) is the total population. The parameters \(\epsilon_j, j = 1, 2\) are modifications parameters, modeling the increased infectiousness in HIV/AIDS and diabetics. The natural death rate \(\mu\) is the same from any compartment and \(\mu_{11}\) and \(\mu_{12}\) are death rate associated with HIV/AIDS and diabetes. The \(\eta\) is defined as the natural rate of progression of tuberculosis. The \(\beta^*\) represents the proportion of active TB cases that are resistant. The \(\omega_1, \omega_2\), are the parameters associated with the transmission of tuberculosis in the HIV/AIDS and diabetes compartments where \(\omega_1, \omega_2 > 1\).

We assume that TB-recovered \(R_i, i = T, H, D\) acquire partial immunity so that from the recovered compartment (the cases that recover) enter the latent compartment with a parameter associated with TB reinfection and reactivation \(\beta_1^*\) with \(\beta_1^* \leq 1\).

We define \(\epsilon_1^*, j = 1, 2\) as the parameters modification associated with resistance to tuberculosis treatment in HIV/AIDS and diabetics.

The \(l_1\) and \(l_2\) are modifications parameters associated with diabetes or HIV infection from the compartments of active TB infection. We define death from TB with a rate \(d_1\), deaths from the combination TB and HIV/AIDS with a rate \(d_2\) and deaths from the combination TB and diabetes with a rate \(d_3\) and we assumed that \(d_3 \geq d_1\) and \(d_2 \geq d_1\) as diabetes and HIV/AIDS experience greater disease induced deaths than their corresponding only TB and we assume death from TB after the use of treatment. The rates \(l_1, l_2\) and \(l_3\) represent the cases that will be MDR-TB (first resistance). The \(p_1, p_2\) and \(p_3\) represent the rates related to developing XDR-TB. The \(l_3\) parameter is associated with the combination of antirretroviral therapy and the treatment of tuberculosis and the possibility of developing diabetes. The \(\eta_{11}, \eta_{12}\) and \(\eta_{13}\) is the recovery rate after being sensitive TB and \(m_1, m_2\) and \(m_3\) is the recovery rate after being MDR-TB. Let’s assume that \(\eta_{11} > m_i\) for \(l = 1, 2, 3\). The \(l_i, l = 1, 2, 3\) are modification parameters associated with TB deaths in MDR-TB cases.

The \(\eta_{11}, \eta_{12}\) and \(\eta_{13}\) are the recovery rate after being XDR-TB. Let’s assume that \(\eta_{11} > m_i\) and \(m_i > \eta_{11}\) for \(l = 1, 2, 3\). The \(l_i, l = 1, 2, 3\) are modification parameters associated with death by TB, death by combination TB-HIV/AIDS and by combination TB-Diabetes after being XDR-TB.

The variables and parameters of the model are represented in the Table 1.

| Parameter or Variable | Description |
|-----------------------|-------------|
| \(S_T, S_H, S_D\)     | Uninfected of TB |
| \(E_T, E_H, E_D\)     | Latently infected |
| \(I\_T, I\_H, I\_D\) | Drug-sensitive TB |
| \(I\_T, I\_H, I\_D\) | MDR-TB infected |
| \(R\_T, R\_H, R\_D\) | XDR-TB infected |
| \(R_T, R_H, R_D\)     | Recovered of TB |
Recruitment rates

$\alpha^*$ Effective contact rates for TB infection

$a_1$ Acquiring diabetes rate

$a_2$ Acquiring HIV rate

$a_4$ Diabetes development rate by use of HIV therapy

$\omega_1, \omega_2, \epsilon_1, \epsilon_2$ Modification parameters

$\mu$ Natural mortality rate

$\eta$ Natural rate of progression to active TB

$t_1, t_2, t_3, t_1', t_2', t_3'$ Modification parameters

$e_1^r, e_2^r, \beta_1^r$ Modification parameters

$d_1$ Resistant TB development rates

$d_4$ TB induced death rate

$d_2$ TB-HIV induced death rate

$d_3$ TB-Diabetes induced death rate

$\mu_{11}, \mu_{12}$ Death rate of HIV/AIDS and diabetes respectively

$m_1, m_2, m_3$ TB recovery rates for MDR-TB

$\beta^*$ Proportion of active TB cases that are resistant.

$\eta_{13r}, \eta_{13t}, \eta_{13s}$ TB recovery rates of drug-sensitive TB infected

$\eta_{14r}, \eta_{15r}, \eta_{16r}$ Resistant (XDR-TB) TB development rates after being MDR-TB

$p_1, p_2, p_3$ Rates related to developing XDR-TB

The effectiveness of the TB treatment with the presence of HIV/AIDS and diabetes is modeled with the following system of differential equations:

$$
\begin{aligned}
\frac{dS_T}{dt} &= f_1 = M_1 - (\mu + a_1 + a_2 + \lambda_T)S_T, \\
\frac{dS_H}{dt} &= f_2 = M_2 + a_2(S_T + S_D) - (a_4 + \mu + \mu_{11} + \omega_1\lambda_T)S_H, \\
\frac{dS_D}{dt} &= f_3 = M_3 + a_4S_H + a_1S_T - (a_2 + \mu + \mu_{12} + \omega_2\lambda_T)S_D, \\
\frac{dI_T}{dt} &= f_4 = \lambda_T(S_T + \beta_1^T R_T) - (a_1 + a_2 + \mu + \eta)I_T, \\
\frac{dE_T}{dt} &= f_5 = \omega_1\lambda_T(S_H + \beta_1^T R_H) + a_2(E_T + E_D) - (e_1^r\eta + \mu + \mu_{11} + \alpha_4)E_H, \\
\frac{dE_D}{dt} &= f_6 = \omega_2\lambda_T(S_D + \beta_1^T R_D) + a_4E_H + a_1E_T - (a_2 + e_2^r\eta + \mu + \mu_{12})E_D, \\
\frac{dD_H}{dt} &= f_7 = (1 - \beta^*)\eta E_T - (l_1 + t_1a_1 + t_2a_2 + \mu + d_1 + \eta_{11})I_{T1}, \\
\frac{dD_D}{dt} &= f_8 = (1 - p_1)\beta^*\eta E_T + (t_1a_1 + t_2a_2 + m_1 + \mu + t'_1d_1 + \eta_{13})I_{T2}, \\
\frac{dI_{H1}}{dt} &= f_9 = t_2a_2(I_{T1} + I_{D1}) + (1 - \beta^*)e_1^r\eta E_H - (l_2 + \mu + \mu_{11} + d_2 + \eta_{12} + t_3a_4)I_{H1}, \\
\frac{dI_{H2}}{dt} &= f_{10} = t_2a_2(I_{T2} + I_{D2}) + (1 - p_2)e_2^*\eta E_H + l_2I_{H1} - (m_2 + \mu + \mu_{11} + l'_2d_2 + \eta_{15} + t_3a_4)I_{H2}, \\
\frac{dD_{H1}}{dt} &= f_{11} = t_1a_1I_{T1} + t_3a_4I_{H1} + (1 - \beta^*)e_2^*\eta E_D - (l_3 + t_2a_2 + \mu + \mu_{12} + d_3 + \eta_{13})I_{D1}, \\
\frac{dD_{H2}}{dt} &= f_{12} = t_1a_1I_{T2} + t_3a_4I_{H2} + (1 - p_3)e_2^*\eta E_D + l_3I_{D1} - (m_3 + t_2a_2 + \mu + \mu_{12} + l'_3d_3 + \eta_{16})I_{D2}, \\
\frac{dR_T}{dt} &= f_{13} = p_1\beta^*\eta E_T + \eta_{14}I_{T1} - (\eta_{11} + t_1a_1 + t_2a_2 + \mu + t'_1d_1)R_{T1}, \\
\frac{dR_H}{dt} &= f_{14} = p_2\beta^*e_1^r\eta E_H + \eta_{15}I_{H1} + t_2a_2(R_{T1} + R_{D1}) - (\eta_{12} + t_3a_4 + \mu + \mu_{11} + l'_2d_2)R_{H1}, \\
\frac{dR_D}{dt} &= f_{15} = p_3\beta^*e_2^*\eta E_D + \eta_{16}I_{D1} + t_3a_4R_{H1} + t_1a_1R_{T1} - (t_2a_2 + \eta_{13} + \mu + \mu_{12} + l'_3d_3)R_{D1}, \\
\frac{dR_T}{dt} &= f_{16} = m_1I_{T2} + \eta_{11}I_{T1} + \eta_{15}R_{T1} - (a_1 + a_2 + \mu + \beta_1^T\lambda_T)R_T, \\
\frac{dR_H}{dt} &= f_{17} = m_2I_{H2} + \eta_{12}I_{H1} + \eta_{16}R_{H1} + a_2(R_{T1} + R_{D1}) - (a_4 + \mu + \mu_{11} + \beta_1^T\omega_1\lambda_T)R_H, \\
\frac{dR_D}{dt} &= f_{18} = m_3I_{D2} + \eta_{13}I_{D1} + \eta_{15}R_{D1} + \alpha_1R_T + \alpha_4R_H - (a_2 + \mu + \mu_{12} + \beta_1^T\omega_2\lambda_T)R_D.
\end{aligned}
$$

(1)
with initial conditions, \( S_I(0) > 0, S_H(0) > 0, S_D(0) > 0, E_T(0) > 0, E_H(0) > 0, E_D(0) > 0, I_T(0) > 0, I_R(0) > 0, I_H(0) > 0, I_D(0) > 0, R_T(0) > 0, R_H(0) > 0, R_D(0) > 0, R_T(0) > 0, R_H(0) > 0 \) and \( R_D(0) > 0 \).

The following results present the existence and positivity of the solution of the system (1) and the region where all variables are always non-negative that is defined as a biologically feasible region. These results and their proof are presented in [25].

**Theorem 1.** Let the initial data for the model (1) be \( S_i(0) > 0, E_i(0) > 0, I_i(0) > 0, I_{rj}(0) > 0, R_{ij}(0) > 0, R_i(0) > 0 \), \( i = T, H, D \). Then the solutions \( (S_i(t), E_i(t), I_i(t), I_{rj}(t), R_{ij}(t), R_i(t)) \), \( i = T, H, D \) of the model (1), with positive initial data, will remain positive for all time \( t > 0 \).

**Theorem 2.** The solutions of model system (1) with non-negative initial conditions exist for all times.

**Lemma 1.** The closed set

\[
\Omega = \left\{ (S_i, E_i, I_i, I_{rj}, R_{ij}, R_i) \in \mathbb{R}^6_+ : N(t) \leq \frac{M_1 + M_2 + M_3}{\mu_2} \right\}
\]

is positively-invariant and attracts all positive solutions of the model (1).

The model (1) is mathematically and epidemiologically well posed in \( \Omega \) which is the biologically feasible region.

The basic reproduction number is found for the different sub-populations (TB-HIV/AIDS, TB-Diabetes and TB-Only) in order to study the transmission of tuberculosis in these sub-populations, using the next generation matrix theory [26]. The basic reproduction numbers and the results relating the stability at the disease-free equilibrium points with the basic reproduction number are given in [25].

The basic reproduction number for the sub-model where we study cases without the presence of HIV/AIDS and diabetes (TB-Only) \((S_H = S_D = E_H = E_D = I_{H1} = I_{H2} = I_{D1} = I_{D2} = R_{H1} = R_{D1} = R_H = R_D = 0)\) is defined as

\[
\mathcal{R}_0^T = \frac{\alpha^* M_1 \left( (1 - \beta^*) \eta (k_{14} k_{15} + l_1 (k_{14} + \eta_{14})) + (1 - p_1) \beta^* \eta k_{12} (k_{14} + \eta_{14}) + k_{12} k_{13} \beta^* \eta p_1 \right)}{N_T (a_1 + a_2 + \mu) k_{11} k_{12} k_{13} k_{14}},
\]

(2)

where \( k_{11} = a_1 + a_2 + \eta + \mu, k_{12} = l_1 t_{1a1} + l_2 t_{2a2} + \mu + d_1 + \eta_{11}, k_{13} = \mu + t_{1d1} + \eta_{14} + m_1 + t_{1a1} + t_{2a2}, k_{14} = \mu + t_{1}^* d_{1} + \eta_{11} + t_{1a1} + t_{2a2} \) and \( N_T = S_T + E_T + I_{T1} + I_{T2} + R_{T1} + R_T \). We have that:

**Lemma 2.** The disease-free equilibrium point \( e_{0}^T \) is locally asymptotically stable when \( \mathcal{R}_0^T < 1 \) and unstable when \( \mathcal{R}_0^T > 1 \).

The basic reproduction number for the sub-model where we study sub-population of TB-HIV/AIDS \((S_D = S_T = E_D = E_T = I_{D1} = I_{D2} = I_{T1} = I_{T2} = R_{T1} = R_T = R_{D1} = R_D = 0)\) is

\[
\mathcal{R}_0^H = \frac{\alpha^* e_1 \omega_1 M_2 \left( (1 - \beta^*) e_{1}^* \eta (k_{23} k_{24} + l_2 (k_{24} + \eta_{15})) + (1 - p_2) e_{1}^* \beta^* \eta k_{22} (k_{24} + \eta_{15}) + k_{22} k_{23} e_{1}^* \beta^* \eta p_2 \right)}{N_H (\alpha_4 + \mu + \mu_1) k_{21} k_{22} k_{23} k_{24}},
\]

(3)

where \( k_{21} = a_4 + e_1 \eta + \mu + \mu_{11}, k_{22} = l_2 + \mu + m_2 + d_2 + \eta_{12} + l_3 a_4, k_{23} = \mu + \mu_1 + t_{2d2} + \eta_{15} + m_2 + t_3 a_4, k_{24} = \mu + \mu_1 + t_2^* d_{2} + \eta_{12} + l_3 a_4, N_H = S_H + E_H + I_{H1} + I_{H2} + R_{H1} + R_H \) and \( N_H = S_H + E_H + I_{H1} + I_{H2} + R_{H1} + R_H \). It follows that:

**Lemma 3.** The disease-free equilibrium \( e_{0}^H \) is asympototically stable when \( \mathcal{R}_0^H < 1 \) and is unstable whenever \( \mathcal{R}_0^H > 1 \).

The basic reproduction number for the TB-Diabetes sub-population \((S_H = S_T = E_H = E_T = I_{H1} = I_{H2} = I_{T1} = I_{T2} = R_{H1} = R_H = R_{T1} = R_T = 0)\) is

\[
\mathcal{R}_0^D = \frac{\alpha^* e_2 \omega_2 M_3 \left( (1 - \beta^*) e_{2}^* \eta (k_{33} k_{34} + l_3 (k_{34} + \eta_{16})) + (1 - p_3) e_{2}^* \beta^* \eta k_{32} (k_{34} + \eta_{16}) + k_{32} k_{33} e_{2}^* \beta^* \eta p_3 \right)}{N_D (\alpha_2 + \mu + \mu_2) k_{31} k_{32} k_{33} k_{34}},
\]

(4)
where \( k_{31} = \alpha_2 + \epsilon_2 \eta + \mu + \mu_{12} \), \( k_{32} = l_3 + \mu + d_3 + \eta_{13} + t_2 \alpha_2 + \mu_{12} \), \( k_{33} = \mu + t_3 d_3 + \eta_{16} + m_3 + t_2 \alpha_2 + \mu_{12} \), \( k_{34} = \mu + \mu_{12} + t_3 d_3 + \eta_{13} + t_2 \alpha_2 \), \( N_D = S_D + E_D + I_D_1 + I_D_2 + R_D_1 + R_D \) and \( N_D = S_D + E_D + I_D_1 + I_D_2 + R_D_1 + R_D \). We have that:

**Lemma 4.** The disease-free equilibrium \( e_0^C \) is asymptotically stable when \( R_0^D < 1 \) and is unstable whenever \( R_0^D > 1 \).

For the full model (1), infection-free equilibrium point is

\[
e_0^C = (S_0^T, S_0^H, S_0^D, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0)
\]

and the dominant eigenvalues of the Jacobian of the full system (1) in the reproduction number of the model (1) is

\[
\mathcal{R}_0 = \max\{\mathcal{R}_0^T, \mathcal{R}_0^H, \mathcal{R}_0^D\}.
\]

### 2.1. Global stability

Now, we list two conditions that if, also guarantee the global asymptotic stability of the disease-free equilibrium point. Following [27], we can rewrite the model (1) as

\[
\begin{align*}
\frac{dS}{dt} &= F(S, I), \\
\frac{dI}{dt} &= G(S, I), \\
G(S, 0) &= 0,
\end{align*}
\]

where \( S \in \mathbb{R}_+^6 \) is the vector whose components are the number of uninfected and recovered individuals \( (S_T, S_H, S_D, R_T, R_H, R_D) \) and \( I \in \mathbb{R}_+^{12} \) denotes the number of infected individuals including the latent and the infectious (the other variables of the model (1)).

The disease-free equilibrium is now denoted by \( E_0^C = (S_0^T, 0) \) where \( S_0^T = (S_0, 0, 0, 0) \) and \( S_0 = (S_0^T, S_0^H, S_0^D) \), \( S_0^T = \left( \frac{M_1}{\mu + \alpha_1 + \alpha_2}, 0 \right), S_0^H = \left( \frac{M_2}{\mu + \mu_{11} + \alpha_4}, 0 \right) \) and \( S_0^D = \left( \frac{M_3}{\mu + \mu_{12} + \alpha_2}, 0 \right) \).

The conditions \( H_1 \) and \( H_2 \) below must be satisfied to guarantee the global asymptotic stability of \( E_0^C \).

\[
\begin{align*}
H_1 : \quad &\text{For } \frac{dS}{dt} = F(S, 0), \quad S_0^T \text{ is globally asymptotically stable}, \\
H_2 : \quad &G(S, I) = AI - G^*(S, I), \quad G^*(S, I) \geq 0, \quad \text{for } (S, I) \in D_1,
\end{align*}
\]

where \( A = D_1 G((S_0^T, 0)) \) ( \( D_1 G((S_0^T, 0)) \) is the jacobian of \( G \) at \( (S_0^T, 0) \)), \( A \) is a M-matrix (the off-diagonal elements of \( A \) are nonnegative) and \( D \) is the biologically feasible region.

If model (1) satisfies the conditions \( H_1 \) and \( H_2 \), then the following results holds;

**Theorem 3.** The fixed point \( E_0^C \) is a globally asymptotically stable equilibrium of model (1) provided that \( \mathcal{R}_0 < 1 \) and that the conditions \( H_1 \) and \( H_2 \) are satisfied.

**Proof.** Let

\[
F(S, 0) = \begin{pmatrix}
M_1 - (\mu + \alpha_1 + \alpha_2)S_T \\
M_2 - (\mu + \mu_{11} + \alpha_4)S_H \\
M_3 - (\mu + \mu_{12} + \alpha_1)S_D \\
0 \\
0 \\
0
\end{pmatrix}.
\]

As \( F(S, 0) \) is a linear equation, we have that \( S_0^T \) is globally stable, hence \( H_1 \) is satisfied. Then,
Our aim with the help of the control optimal theory is to decrease the total number of patients with adherence to antiretroviral treatment, stimulation of a good (healthy) diet, physical exercise, among others. How to maintain an active immune system, particularly immunocompromised patients (HIV/AIDS) should occur in up to 15 days. Monthly consultations until the end of the TB treatment. Consultations by other members of the multi-professional team, with the objective of promoting adherence to treatment, prevent possible reinfection or reactivation of the bacteria, scheduling medical consultations, and lab tests periodically. Control of entry of new genotypes of TB into the population. Also, to inform patients how to maintain an active immune system, particularly immunocompromised patients (HIV/AIDS) with adherence to antiretroviral treatment, stimulation of a good (healthy) diet, physical exercise, among others.

Since \( S_T + \beta_1 R_T, S_H + \beta_2 R_H \) and \( S_D + \beta_1 R_D \) are always less than or equal to \( N_T, \frac{S_T + \beta_1 R_T}{N} \leq 1 \), \( \frac{S_H + \beta_1 R_H}{N} \leq 1 \) and \( \frac{S_D + \beta_1 R_D}{N} \leq 1 \). Thus \( G^*(S, I) \geq 0 \) for all \((S, I) \in D\). The \( E_0^C \) is a globally asymptotically stable. \( \square \)

3. Model with controls and optimal control problem

3.1. Definition of controls and its policy

Our aim with the help of the control optimal theory is to decrease the total number of patients with MDR-TB and XDR-TB during a period of time \([t_0, t_f]\). The control strategy is decomposed in four controls \( u_0, u_{11}, u_{12} \) and \( u_{13} \) defined as follows:

- \( u_0(t) \) (control over reinfection and reactivation)- this refers to preparing patients recovering from TB to avoid possible reinfection or reactivation of the bacteria, scheduling medical consultations, and lab tests periodically. Control of entry of new genotypes of TB into the population. Also, to inform patients how to maintain an active immune system, particularly immunocompromised patients (HIV/AIDS) with adherence to antiretroviral treatment, stimulation of a good (healthy) diet, physical exercise, among others.
- \( u_{11}(t) \) (control for TB-Only)- this includes personal respiratory protection, educational programs for public health, activities that ensure treatment completion to reduce relapse following treatment. Patients receiving treatment for MDR-TB should be monitored to ensure the completion of the treatment. As part of this control, it is needed to check blood glucose levels and make HIV tests to determine if the person is diabetic and/or HIV positive.
- \( u_{12}(t) \) (control for HIV/AIDS cases)- the control will be based on clinical follow-up (we assume all cases are diagnosed), and we consider all cases are using antiretroviral therapy and have a follow-up on their CD4 count and viral load. In particular, from the beginning of treatment for TB, the return of the patient should occur in up to 15 days. Monthly consultations until the end of the TB treatment. Consultations by other members of the multi-professional team, with the objective of promoting adherence to treatment,
identifying interoccurrences that may interfere with the correct use of TB drugs and antiretrovirals. Another important element is to check blood glucose levels and determine if the person is diabetic.

- $u_{13}(t)$ (control for diabetics cases) - the control is focused on monitoring glycemic parameters throughout TB treatment, and promoting adherence to treatment, identifying interoccurrences that may interfere with the efficacy of TB treatment. Another important factor is to make HIV tests to control the exits of this subpopulation.

In particular, $u_{11}(t)$ is the control in the entrance to compartment $I_{T_2}, R_{T_1}, u_{12}(t)$ is the control in the entrance to compartment $I_{T_3}, R_{H_1}$ and $u_{13}(t)$ is the control in the entrance to compartment $I_{D_2}, R_{D_1}$. The $u_0(t)$ controls entry into the $E_T, E_H$ and $E_D$ compartments by reinfection or reactivation. Eqs (7) shows the incorporation of the controls in the compartments of model (1) and the other equations remain the same as the uncontrolled model (1). The $(1-u_0), (1-u_{11}), (1-u_{12})$ and $(1-u_{13})$ representing effort that prevents failure of the treatment. The Figure 1 shows the control dynamics.

\[
\begin{align*}
\frac{dE_T}{dt} &= \lambda_T(S_T + (1-u_0)\beta_1 R_T) - (\alpha_1 + a_2 + \mu + \eta)E_T, \\
\frac{dE_H}{dt} &= \omega_1 \lambda_T(S_H + (1-u_0)\beta_1 R_H) + a_3 E_T + E_D) - (\alpha_2 + \eta + \mu + \mu_1 + \alpha_4)E_H, \\
\frac{dE_D}{dt} &= \omega_2 \lambda_T(S_D + (1-u_0)\beta_1 R_D) + a_4 E_H + a_5 E_T - (\alpha_2 + \epsilon_2 \eta + \mu + \mu_2)E_D, \\
\frac{dt_1}{dt} &= (1-\beta_1 \eta)E_T - (1-11)l_1 + a_1 + a_2 + \mu + d_1 + \eta_1)I_{T_1}, \\
\frac{dt}{dt} &= (1-p_1)\beta_1 \eta E_T + (1-u_{11})l_1 I_{T_1} - (a_1 + a_2 + m_1 + \mu + d_1 + (1-u_{11})\eta_1)I_{T_1}, \\
\frac{dI_1}{dt} &= t_2 a_2(I_{T_1} + I_{D_1}) + (1-\beta_1)\epsilon_1 \eta E_H - (1-u_{12})l_2 + \mu + \mu_1 + d_2 + \eta_1 + \mu_4)I_{H_1}, \\
\frac{dI_2}{dt} &= t_2 a_2(I_{T_1} + I_{D_1}) + (1-p_2)\beta_2^* \epsilon_2 \eta E_H + (1-u_{12})l_2 I_{H_1} - (m_2 + \mu + \mu_1 + d_2 + (1-u_{12})\eta_1 + \mu_4)I_{H_1}, \\
\frac{dD_1}{dt} &= t_1 a_1 l_{T_1} + a_4 I_{H_1} + (1-\beta_1)\epsilon_2 \eta E_D - (1-u_{13})l_3 + a_1 + \mu + d_3 + \eta_3 + \mu_4)D_{D_1}, \\
\frac{dD_2}{dt} &= t_1 a_1 l_{T_1} + a_4 I_{H_1} + (1-p_3)\epsilon_3 \eta E_D + (1-u_{13})l_3 D_{D_1} - (m_3 + t_2 a_2 + \mu + d_3 + (1-u_{13})\eta_1 + \mu_4)D_{D_1}, \\
\frac{dR_1}{dt} &= \beta_1 \eta E_T + (1-u_{11})\eta_1 I_{T_1} - (\eta_1 + t_1 a_1 + t_2 a_2 + \mu + d_1)R_{T_1}, \\
\frac{dR_2}{dt} &= \beta_2 \epsilon_1 \eta E_H + (1-u_{12})\eta_2 I_{H_1} + t_2 a_2(R_{T_1} + R_{D_1}) - (\eta_1 + t_2 a_4 + \mu + \mu_1 + d_2)R_{H_1}, \\
\frac{dR_3}{dt} &= \beta_2 \epsilon_2 \eta E_D + (1-u_{13})\eta_1 I_{D_1} + t_3 a_4(R_{H_1} + t_1 a_1 R_{T_1} + (t_2 a_2 + \eta_1 + \mu + \mu_1 + d_3)R_{D_1}, \\
\frac{dR_4}{dt} &= m_1 I_{T_1} + \eta_1 I_{H_1} + \eta_1 I_{R_{T_1}} - (a_1 + a_2 + \mu + (1-u_0)\beta_1 \omega T)R_{T_1}, \\
\end{align*}
\]
3.2. Optimal control problem and its analysis

Our objective functional to be minimized is

\[ J(u_0, u_{11}, u_{12}, u_{13}) = \int_{t_0}^{t_f} \left( E_T(t) + E_H(t) + E_D(t) \right) + \left( I_T(t) + I_H(t) + I_D(t) \right) + \left( R_T(t) + R_H(t) + R_D(t) \right) \]

\[ + \frac{1}{2} \left( B_0 u_0^2(t) + (B_1 + B_4) u_1^2(t) + (B_2 + B_5) u_2^2(t) + (B_3 + B_6) u_3^2(t) \right) dt. \]

The structure of our functional is consistent with recent works as \([12–19]\).

The coefficients \( B_m, m = 0, 1, \ldots, 6 \) represent the costs associated with the respective costs of implementing the relevant control strategies on a finite time horizon \([t_0, t_f]\) (where initial time \(t_0 = 0\), final time \(t_f = 10\) year period) and consists in the cost induced by the efforts of the three different types of control. The \( B_1, B_2 \) and \( B_3 \) are associated with the implementation of control on the MDR-TB and XDR-TB. Given the characteristics of resistance to tuberculosis and its treatment, which in some cases may include hospitalization, high drug costs, the use of other drugs to stimulate the immune system, among others, let’s assume that \( B_1 < B_4, B_2 < B_5 \) and \( B_3 < B_6 \) and these constants cannot be neither zeros nor very large (realistic values).

The cost involved in the control about the compartments \( I_T(t), I_H(t) \) and \( I_D(t) \) is taken as \( \int_{t_0}^{t_f} \frac{B_1 u_1^2(t)}{2} \), \( \int_{t_0}^{t_f} \frac{B_2 u_2^2(t)}{2} \), \( \int_{t_0}^{t_f} \frac{B_3 u_3^2(t)}{2} \), \( \int_{t_0}^{t_f} \frac{B_4 u_4^2(t)}{2} \), \( \int_{t_0}^{t_f} \frac{B_5 u_5^2(t)}{2} \), \( \int_{t_0}^{t_f} \frac{B_6 u_6^2(t)}{2} \) for \( E_T(t), E_H(t) \) and \( E_D(t) \). We seek to find the optimal controls \( u_0^*, u_{11}^*, u_{12}^*, u_{13}^* \) that satisfy

\[ J(u_0^*, u_{11}^*, u_{12}^*, u_{13}^*) = \min_{U_{ad}} J(u_0, u_{11}, u_{12}, u_{13}), \]

where \( U_{ad} = \{(u_0, u_{11}, u_{12}, u_{13}) \mid u_{0,11}, u_{12}, u_{13}\text{ Lebesgue Integrable } 0 \leq u_k \leq 1 \ k = 0, 11, 12, 13 \ \forall t \in [t_0, t_f]\} \).

3.2.1. The necessary and sufficient conditions of optimal control

We will study the sufficient conditions for the existence of an optimal control for our controls system using the conditions in Theorem 4.1 and its corresponding Corollary in \([28]\). After that, we will characterize the optimal control functions by using Pontryagin’s Maximum Principle and then we derive necessary conditions for our control problem. We have that solutions of the controls system are bounded and non-negative for finite time interval in the biologically feasible region. These results are important to establish the existence of an optimal control.

We denote the vector of states \( \bar{x} = [S_T, S_H, S_D, E_T, E_H, E_D, I_T, I_H, I_D, I_{12}, I_{13}, I_{12}, I_{13}, R_T, R_H, R_D]^T \) and the controls vector \( \bar{u} = [u_0, u_{11}, u_{12}, u_{13}]^T \).

**Theorem 4.** There exists an optimal control \( u^* = (u_{0}^*, u_{11}^*, u_{12}^*, u_{13}^*) \) to problem

\[ \min J(u_0, u_{11}, u_{12}, u_{13}) \text{ subject to model (1) with controls} \]

where \( u^* \in U_{ad} \).

**Proof.** We use the requirements of Theorem 4.1 and Corollary 4.2 in \([28]\) to prove the Theorem 4. Let \( l(t, \bar{x}, \bar{u}) \) as the right-hand of (1) with controls. We will show that the following requirements are satisfied:

I. \( l \) is of class \( C^1 \) and there exist a constant \( C \) such that

\[ |l(t, 0, 0, 0)| \leq C, \quad |l_s(t, \bar{x}, \bar{u})| \leq C(1 + |\bar{u}|), \quad |l_{ss}(t, \bar{x}, \bar{u})| \leq C. \]

II. The admissible set \( F \) of all solution to system (1) with controls in \( U_{ad} \) is non-empty;

III. \( l(t, \bar{x}, \bar{u}) = a_1(t, \bar{x}) + a_2(t, \bar{x})\bar{u}; \)

IV. The control set \( C = [0, 1] \times [0, 1] \times [0, 1] \) is closed, convex and compact;

V. The integrand of the objective functional is convex in \( U \).
We can write system (1) with controls as

\[
\begin{align*}
M_1 - (\mu + a_1 + a_2 + \lambda T) & S_T \\
M_2 + a_3 (S_T + S_D) - (a_4 + \mu + \mu_1 + \omega_1 \lambda) & S_H \\
M_3 + a_4 S_1 + a_5 & S_T - (a_2 + \mu + \mu_2 + \omega_2 \lambda) & S_D \\
\lambda T (S_T + (1 - u_0) \beta_1 R_T) - (a_1 + a_2 + \mu + \eta) & E_T \\
\omega_1 \lambda T (S_H + (1 - u_0) \beta_1 R_H) + a_2 (E_T + E_D) - (c_1 \eta + \mu + \mu_1 + a_4) & E_H \\
\omega_2 \lambda T (S_D + (1 - u_0) \beta_1 R_D) + a_4 E_H + a_3 E_T - (a_2 + c_2 \eta + \mu + \mu_2) & E_D \\
(1 - \beta^T) \eta E_T - ((1 - u_1) \lambda T + \lambda T_1 + t_2 a_2 + m_1 + \mu + t_1 d_1 + (1 - u_1) \eta_{14}) & T_{12} \\
t_2 a_2 (T_{12} + I_{21}) + (1 - \beta^T) e_1 \eta E_H - ((1 - u_1) \lambda T + \lambda T_1 + t_2 a_2 + m_1 + \mu + t_1 d_1 + (1 - u_1) \eta_{14}) & T_{11} \\
t_2 a_2 (I_{12} + I_{21}) + (1 - \beta^T) e_1 \eta E_D - ((1 - u_1) \lambda T + \lambda T_1 + t_2 a_2 + m_1 + \mu + t_1 d_1 + (1 - u_1) \eta_{14}) & T_{13} \\
t_1 a_1 T_{12} + t_3 a_4 H_{12} + (1 - \beta^T) e_2 \eta E_D + (1 - u_1) t_3 I_{21} - (m_2 + t_2 a_2 + m_1 + t_2 d_2 + (1 - u_1) \eta_{15} + t_3 a_4) & H_{12} \\
(l_1 \eta E_T - (1 - u_1) \eta_{14} I_{12}) - (\eta_{11} + t_1 a_1 + t_2 a_2 + m_1 + (1 - u_0) \beta_1 \lambda T) & R_T \\
P_2 e_1^T \eta E_H + (1 - u_1) \eta_{15} I_{12} + t_2 a_2 (R_T + R_D) - (\eta_{12} + t_3 a_4 + \mu + \mu_1 + t_2 d_2) & R_H \\
P_3 e_2^T \eta E_D + (1 - u_1) \eta_{16} I_{12} + t_3 a_4 R_H + t_1 a_1 R_T - (t_2 a_2 + \eta_{15} + \mu + \mu_2 + t_2 d_2) & R_D \\
M_1 t_2 + \eta_{11} T_1 + \eta_{16} R_T - (a_1 + a_2 + \mu + (1 - u_0) \beta_1 \lambda T) & R_T \\
m_2 t_2 + \eta_{12} R_H + (a_2 + (1 - u_0) \beta_1 \omega_1 \lambda T) & R_H \\
m_3 t_3 + \eta_{15} R_D + (a_1 + a_2 + (1 - u_0) \beta_1 \omega_2 \lambda T) & R_D \\
(0, 0, 0, 0) & (0, 0, 0, 0) & (0, 0, 0, 0) & (0, 0, 0, 0)
\end{align*}
\]

Then, we have \( l(t, \vec{x}, \vec{u}) \) is of class \( C^1 \) by the model construction. Let's

\[
|l_0(t, \vec{x}, \vec{u})| = \begin{cases}
0 & 0 & 0 & 0 \\
0 & 0 & 0 & 0 \\
\beta_1 \lambda T R_T & 0 & 0 & 0 \\
\beta_1 \omega_1 \lambda T R_H & 0 & 0 & 0 \\
\beta_1 \omega_2 \lambda T R_D & 0 & 0 & 0
\end{cases}
\]

\[
l_1(t, \vec{x}, \vec{u}) = [AB],
\]

where

\[
A = \begin{pmatrix}
-\alpha_3 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
-\alpha_2 & -\alpha_3 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & -\alpha_3 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & (1 - \beta^T) \eta & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & (1 - \beta^T) \eta & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
\cdots & \cdots & \cdots & \cdots & \cdots & \cdots & \cdots & \cdots & \cdots & \cdots & \cdots \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
0 & 0 & 0 & 0 & 0 & 0 & 0 & -c_1 & -c_1 & -c_1 & -c_1 \\
\end{pmatrix}.
\]
where \( c_1 = \frac{\alpha^* S_T}{N}c_2 = \frac{\omega_2 \alpha^* S_H}{N}c_3 = \frac{\omega_2 \alpha^* S_D}{N}c_4 = c_1 + \frac{(1 - u_0) \beta_1 \alpha^* R_T}{N}c_5 = c_2 + \frac{(1 - u_0) \beta_1 \omega_2 \alpha^* R_H}{N}c_6 = c_3 + \frac{(1 - u_0) \beta_1 \omega_2 \alpha^* R_D}{N}
\)

\( k_{10} = \mu + a_1 + a_2 + \lambda_T, k_{20} = \mu + a_1 + a_4 + \omega_1 \lambda_T, k_{30} = \mu + a_2 + \omega_2 \lambda_T, k_{40} =
\mu + a_1 + a_2 + (1 - u_0) \beta_1 \omega_2 \lambda_T, k_{50} = \mu + a_1 + a_4 + (1 - u_0) \beta_1 \omega_1 \lambda_T, k_{60} = \mu + a_2 + (1 - u_0) \beta_1 \omega_2 \lambda_T. \)

The \( k_{12}, k_{13}, k_{22}, k_{23}, k_{32} \) and \( k_{33} \) represent the \( k_{12}, k_{13}, k_{22}, k_{23}, k_{32} \) and \( k_{33} \), with the respective control expressions. We have that

\[
|l(t, 0, 0)| = \left(\frac{M_1, M_2, M_3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0}{T}\right).
\]

All the variables of the model are positive and bounded by definition of the \( \Omega \) (biologically feasible region). Remember that,

\[
\Omega = \left\{ (S_i, E_i, I_i, I_{1i}, R_i, R_i) \in \mathbb{R}_{+}^{18}, i = T, H, D : N(t) \leq \frac{M_1 + M_2 + M_3}{\mu} \right\},
\]

where \( N(t) \) is the total population. Then, there exists a constant \( C \) such that

\[
|l(t, 0, 0)| \leq C, \quad |l_t(t, \bar{x}, \bar{u})| \leq C(1 + |\bar{u}|), \quad |l_a(t, \bar{x}, \bar{u})| \leq C.
\]

Thus condition I. is satisfied.

By the construction of the model and the condition \( L \), system (1) with controls has a unique solution for constant controls, this implies that condition II. is satisfied.

We can write the system (1) with controls as

\[
l(t, \bar{x}, \bar{u}) = \begin{cases} 
M_1 - (\mu + a_1 + a_2 + \lambda_T) S_T \\
M_2 + a_2 (S_T + S_D) - (a_4 + \mu + a_1 + a_2 + \omega_1 \lambda_T) S_H \\
M_3 + a_4 S_H + a_1 S_T - (a_2 + \mu + a_2 + \omega_2 \lambda_T) S_D \\
\lambda_T S_T - (a_1 + a_2 + \mu + \eta) E_T \\
\omega_1 \lambda_T S_H + a_2 (E_T + E_D) - (\epsilon_1 \eta + \mu + a_1 + a_4) E_H \\
\omega_2 \lambda_T S_D + a_4 E_H + a_2 E_T - (a_2 + \epsilon_2 \eta + \mu + a_2 + a_4) E_D \\
(1 - \beta^*) \eta E_T - (t_1 a_1 + t_2 a_2 + \mu + a_1 + d_1 + d_1) I_{1i} \\
(1 - p_1) \beta^* \eta E_T - (t_1 a_1 + t_2 a_2 + \mu + a_1 + d_1) I_{2i} \\
t_2 a_2 (I_{1i} + I_{2i}) + (1 - \beta^*) \epsilon_1 \eta E_H + (\mu + a_1 + d_2 + \eta_1 + t_3 a_1) I_{1i} \\
t_2 a_2 (I_{1i} + I_{2i}) + (1 - \beta^*) \epsilon_2 \eta E_H - (\mu + a_1 + d_2 + \eta_1 + t_3 a_1) I_{1i} \\
t_1 a_1 I_{1i} + t_3 a_1 I_{1i} + (1 - \beta^*) \epsilon_1 \eta E_H - (t_2 a_2 + \mu + a_2 + d_3 + \eta_1) I_{1i} \\
t_1 a_1 I_{2i} + t_3 a_1 I_{2i} + (1 - \beta^*) \epsilon_2 \eta E_H - (t_2 a_2 + \mu + a_2 + d_3) I_{2i} \\
p_1 \beta^* \eta E_T - (t_1 I_{1i} + t_2 a_2 + \mu + \mu d_1) R_{1i} \\
p_2 \beta^* \eta E_H + t_2 a_2 (R_{1i} + R_{2i}) - (\eta_{11} + t_3 a_4 + \mu + \mu + t_4 d_1) R_{1i} \\
p_3 \beta^* \eta E_D + t_4 a_4 R_{1i} + t_1 a_1 R_{1i} - (t_2 a_2 + \eta_{13} + \mu + \mu + t_3 d_1) R_{1i} \\
m_1 I_{1i} + \eta_{11} I_{1i} + \eta_{11} R_{1i} - (a_1 + a_2 + \mu) R_{1i} \\
m_2 I_{2i} + t_3 a_1 I_{2i} + a_2 (R_{1i} + R_{2i}) - (a_2 + a_1 + a_3) R_{1i} \\
m_3 I_{2i} + t_3 a_1 I_{2i} + \eta_{13} R_{1i} + a_1 R_{1i} + a_4 R_{1i} - (a_2 + \mu + a_2 + a_4) R_{1i}
\end{cases}
\]

Then, \( l(t, \bar{x}, \bar{u}) = a_1 (t, \bar{x}) + a_2 (t, \bar{x}) \bar{u} \).

This means that condition III. holds. By construction the sets \( U \) is closed, convex and compact and condition IV. is satisfied.
Now, we are going to prove the convexity of the integrand in the objective functional
\[
f(t, \bar{x}, \bar{u}) = E_T(t) + E_H(t) + E_D(t) + I_{T_2}(t) + I_{H_2}(t) + I_{D_2}(t) + I_{T_3}(t) + I_{H_3}(t) + I_{D_3}(t) + \frac{B_0u_0^2(t)}{2} + \frac{(B_1 + B_4)u_{11}^2(t)}{2} + \frac{(B_2 + B_3)u_{12}^2(t)}{2} + \frac{(B_3 + B_6)u_{13}^2(t)}{2},
\]
this implies proving that
\[(1 - q)f(t, \bar{x}, \bar{u}) + qf(t, \bar{x}, \bar{v}) \geq f(t, \bar{x}, (1 - q)\bar{u} + q\bar{v}),\]
where \(\bar{u}, \bar{v}\) are two control vectors with \(q \in [0, 1]\). It follows that
\[
(1 - q)f(t, \bar{x}, \bar{u}) + qf(t, \bar{x}, \bar{v}) = (1 - q)\left( E_T + E_H + E_D + I_{T_2} + I_{H_2} + I_{D_2} + I_{T_3} + I_{H_3} + I_{D_3} + \frac{B_0u_0^2}{2} + \frac{(B_1 + B_4)u_{11}^2}{2} + \frac{(B_2 + B_3)u_{12}^2}{2} + \frac{(B_3 + B_6)u_{13}^2}{2} \right) + q\left( E_T + E_H + E_D + I_{T_2} + I_{H_2} + I_{D_2} + I_{T_3} + I_{H_3} + I_{D_3} + \frac{B_0(u_0^2 + (1 - q)u_0^2) + (B_1 + B_4)(u_{11}^2 + (1 - q)u_{11}^2) + (B_2 + B_3)(u_{12}^2 + (1 - q)u_{12}^2) + (B_3 + B_6)(u_{13}^2 + (1 - q)u_{13}^2)}{2} \right)
\]
and
\[
f(t, \bar{x}, (1 - q)\bar{u} + q\bar{v}) = E_T + E_H + E_D + I_{T_2} + I_{H_2} + I_{D_2} + I_{T_3} + I_{H_3} + I_{D_3} + \frac{B_0}{2}\left[ (1 - q)u_0^2 + qv_0^2 \right] + \frac{(B_1 + B_4)}{2}\left[ (1 - q)u_{11}^2 + qv_{11}^2 \right] + \frac{(B_2 + B_3)}{2}\left[ (1 - q)u_{12}^2 + qv_{12}^2 \right] + \frac{(B_3 + B_6)}{2}\left[ (1 - q)u_{13}^2 + qv_{13}^2 \right] \geq 0.
\]
With this, we prove the requirement V. and the proof of the theorem is complete. \(\square\)

The Pontryagin’s Maximum Principle provides the necessary conditions an optimal control must satisfy. Firstly, the Hamiltonian for the control problem is defined by
\[
H = E_T(t) + E_H(t) + E_D(t) + I_{T_2}(t) + I_{H_2}(t) + I_{D_2}(t) + R_{T_1}(t) + R_{H_1}(t) + R_{D_1}(t) + \frac{B_0u_0^2(t)}{2} + \frac{(B_1 + B_4)u_{11}^2(t)}{2} + \frac{(B_2 + B_3)u_{12}^2(t)}{2} + \frac{(B_3 + B_6)u_{13}^2(t)}{2} + \sum_{n=1}^{18} \lambda_nf_n
\]
where \(\lambda_1, \lambda_2, \cdots, \lambda_{18}\) are the adjoint variables. Now, we are going to prove the following theorem:
Theorem 5. Given an optimal controls \(u_0, u_{11}, u_{12}, u_{13}\) and associated solutions \(S^*_T, S^*_H, S^*_D, E^*_T, E^*_H, E^*_D, I^*_T, I^*_H, I^*_D, R^*_T, R^*_H, R^*_D\), that minimizes \(J(u_0, u_{11}, u_{12}, u_{13})\) over the domain \(U_{ad}\), there exist adjoint function, \(\lambda_n(t)\), \(n = 1, \ldots, 18\) that satisfy:

\[
\frac{d\lambda_n}{dt} = -\frac{\partial H}{\partial x_i}
\]

where \(x_i = S_T, S_H, S_D, E_T, E_H, E_D, I_T, I_H, I_D, R_T, R_H, R_D\). In association with the transversality conditions \(\lambda_n(t_f) = 0\) for \(n = 1, 2, \ldots, 18\). Moreover, the following characterization holds

\[
\begin{align*}
\lambda_0^* &= \min \left\{ \max \left\{ 0, \beta_1^*(\lambda_4 - \lambda_6) R_T + \omega_1(\lambda_5 - \lambda_7) R_H + \omega_2(\lambda_6 - \lambda_1) R_D \right\} \right\}, \\
\lambda_{11}^* &= \min \left\{ \max \left\{ 0, \frac{l_1 I_1 (\lambda_5 - \lambda_7) + \eta_{14} I_2 (\lambda_1 - \lambda_8)}{B_1 + B_4} \right\} \right\}, \\
\lambda_{12}^* &= \min \left\{ \max \left\{ 0, \frac{l_2 I_1 (\lambda_{10} - \lambda_9) + \eta_{15} I_2 (\lambda_{14} - \lambda_{10})}{B_2 + B_5} \right\} \right\}, \\
\lambda_{13}^* &= \min \left\{ \max \left\{ 0, \frac{l_3 I_1 (\lambda_{12} - \lambda_{11}) + \eta_{16} I_2 (\lambda_{15} - \lambda_{12})}{B_3 + B_6} \right\} \right\}.
\end{align*}
\]

(10)

Proof. Using Pontryagin’s Maximum Principle [29], the adjoint equations are obtained:
\[
\frac{d\lambda_{12}}{dt} = -\frac{\partial H}{\partial D_{2}} = -1 + \frac{\alpha^*}{N} e_2 ((\lambda_1 - \lambda_4) S_T + \omega_1 S_H (\lambda_2 - \lambda_5) + \omega_2 S_D (\lambda_3 - \lambda_6) + (1 - u_0) \beta'_1 (R_T (\lambda_1 - \lambda_4) + \omega_1 R_H (\lambda_1 - \lambda_5) + \omega_2 R_D (\lambda_1 - \lambda_6)) + t_2 \alpha_2 (\lambda_{12} - \lambda_{10}) + m_3 (\lambda_{12} - \lambda_{18}) + (1 - u_{13}) \eta_{16} (\lambda_{12} - \lambda_{15}) + (\mu + \mu_{12} + \lambda^* d_3) \lambda_{12},
\]
\[
\frac{d\lambda_{13}}{dt} = -\frac{\partial H}{\partial R_{T_1}} = -1 + \frac{\alpha^*}{N} \left((\lambda_1 - \lambda_4) S_T + \omega_1 S_H (\lambda_2 - \lambda_5) + \omega_2 S_D (\lambda_3 - \lambda_6) + (1 - u_0) \beta'_1 (R_T (\lambda_1 - \lambda_4) + \omega_1 R_H (\lambda_1 - \lambda_5) + \omega_2 R_D (\lambda_1 - \lambda_6)) + \eta_{11} (\lambda_{13} - \lambda_{16}) + t_1 \alpha_1 (\lambda_{13} - \lambda_{15}) + t_2 \alpha_2 (\lambda_{13} - \lambda_{14}) + (\mu + \mu_{11} + \lambda^* d_1) \lambda_{13},
\]
\[
\frac{d\lambda_{14}}{dt} = -\frac{\partial H}{\partial R_{H_1}} = -1 + \frac{\alpha^*}{N} e_1 ((\lambda_1 - \lambda_4) S_T + \omega_1 S_H (\lambda_2 - \lambda_5) + \omega_2 S_D (\lambda_3 - \lambda_6) + (1 - u_0) \beta'_1 (R_T (\lambda_1 - \lambda_4) + \omega_1 R_H (\lambda_1 - \lambda_5) + \omega_2 R_D (\lambda_1 - \lambda_6)) + \eta_{12} (\lambda_{14} - \lambda_{17}) + t_3 \alpha_4 (\lambda_{14} - \lambda_{15}) + (\mu + \mu_{11} + \lambda^* d_2) \lambda_{14},
\]
\[
\frac{d\lambda_{15}}{dt} = -\frac{\partial H}{\partial D_{1}} = -1 + \frac{\alpha^*}{N} e_2 ((\lambda_1 - \lambda_4) S_T + \omega_1 S_H (\lambda_2 - \lambda_5) + \omega_2 S_D (\lambda_3 - \lambda_6) + (1 - u_0) \beta'_1 (R_T (\lambda_1 - \lambda_4) + \omega_1 R_H (\lambda_1 - \lambda_5) + \omega_2 R_D (\lambda_1 - \lambda_6)) + \eta_{13} (\lambda_{15} - \lambda_{18}) + t_2 \alpha_2 (\lambda_{15} - \lambda_{14}) + (\mu + \mu_{12} + \lambda^* d_3) \lambda_{15},
\]
\[
\frac{d\lambda_{16}}{dt} = -\frac{\partial H}{\partial R_T} = (1 - u_0) \beta'_1 \lambda_T ((\lambda_1 - \lambda_4) R_T + \omega_1 (\lambda_1 - \lambda_5) R_H + \omega_2 (\lambda_1 - \lambda_6) R_D) = 0,
\]
which implies that
\[
u_k^* = \frac{\beta'_1 \lambda_T ((\lambda_1 - \lambda_4) R_T + \omega_1 (\lambda_1 - \lambda_5) R_H + \omega_2 (\lambda_1 - \lambda_6) R_D)}{B_0}.
\]
on the set \( \{ t : 0 < u_0^* (t) < 1 \} \).
\[
\frac{\partial H}{\partial u_{11}} = (B_1 + B_4) u_{11} + l_1 I_{H_1} (\lambda_7 - \lambda_8) + \eta_{14} I_{T_2} (\lambda_8 - \lambda_{13}) R_D = 0,
\]
which implies that
\[
u_{11}^* = \frac{l_1 I_{H_1} (\lambda_8 - \lambda_7) + \eta_{14} I_{T_2} (\lambda_{13} - \lambda_8)}{B_1 + B_4},
\]
on the set \( \{ t : 0 < u_{11}^* (t) < 1 \} \).

Analogously, for the optimal control \( u_{12}^* \), we have
\[
\frac{\partial H}{\partial u_{12}} = (B_2 + B_5) u_{12} + l_2 I_{H_1} (\lambda_9 - \lambda_{10}) + \eta_{15} I_{H_2} (\lambda_{10} - \lambda_{14}) R_H = 0.
\]
Therefore,
\[
u_{12}^* = \frac{l_2 I_{H_1} (\lambda_{10} - \lambda_9) + \eta_{15} I_{H_2} (\lambda_{14} - \lambda_{10})}{B_2 + B_5},
\]
on the set \( \{ t : 0 < u_{12}^* (t) < 1 \} \). For the control \( u_{13}^* \), we obtained
\[
\frac{\partial H}{\partial u_{13}} = (B_3 + B_6) u_{13} + l_3 I_{D_1} (\lambda_{11} - \lambda_{12}) + \eta_{16} I_{D_2} (\lambda_{12} - \lambda_{15}) = 0,
\]
and this implies that
\[ u_{13}^* = \frac{l_3 I_{D_4} (\lambda_{12} - \lambda_{11}) + \eta_{16} I_{D_5} (\lambda_{15} - \lambda_{12})}{B_3 + B_6} , \]
on the control set \( \{ t : 0 < u_{13}(t) < 1 \} \).

Note that the optimality conditions only hold on the interior of the control set.

4. Numerical Results

The aim of this section is to simulate the application of the controls in the population. First, we solve
the optimality system numerically using an iterative method based on the fourth-order Runge-Kutta. We use
the forward-backward sweep method for finding the solution of the optimality system which has the state
Eq. (1), adjoint Eq. (11), control characterizations (10), and initial/final condition (initial and transversality
conditions). The method starts with initial values for the optimal control and we solve the state system
forward in time using the Runge-Kutta method of the fourth-order. Following, we solve the adjoint equation
backward in time with Runge-Kutta of the fourth-order using the state variables, initial control guesses, and
transversality conditions. The controls \( u_0(t) \), \( u_{11}(t) \), \( u_{12}(t) \) and \( u_{13}(t) \) are updated and used to solve the state
and adjoint system respectively. This iterative process continues until that current state, adjoint, and control
values converge [19,30].

For the numerical simulations, we use a set of parameters extracted from [31–41] with purposes
illustrative and to support the analytical results, see Table 2.

The initial conditions for the TB-Only and TB-Diabetes sub-populations are taken from [31], and the
values for the sub-population of HIV/AIDS are assumed and do not represent a specific demographic area, but
fall within the range of actual achievable data, see Table 2. The values of the parameters and initial conditions
that are assumed are discussed and validated with the specialists. We assume that \( B_0 = 200 \), \( B_1 = 50 \), \( B_2 = 150 \),
\( B_3 = 75 \), \( B_4 = 100 \), \( B_5 = 250 \) and \( B_6 = 150 \).

We assume that always apply control in the HIV/AIDS sub-population because tuberculosis is classified
as an opportunistic disease and HIV/AIDS cases are monitored by the use of antiretroviral therapy. Also,
reinfection or reactivation of TB is always controlled in all strategies because of its impact on treatment
resistance. Then, our control strategies are defined as the combination of efforts and are defined as:

**Strategy I.** We activate all controls \( (u_0(t) > 0, u_{11}(t) > 0, u_{12}(t) > 0, u_{13}(t) > 0) \).

**Strategy II.** Combination of \( u_0(t) \), \( u_{11}(t) \), \( u_{12}(t) \) while setting \( u_{13}(t) = 0 \) \((u_0(t) > 0, u_{11}(t) > 0, u_{12}(t) > 0 \)
and \( u_{13}(t) = 0) \).

**Strategy III.** Combination of \( u_0(t) \), \( u_{12}(t) \), \( u_{13}(t) \) while setting \( u_{11}(t) = 0 \) \((u_0(t) > 0, u_{12}(t) > 0, u_{13}(t) > 0 \)
and \( u_{11}(t) = 0) \).

We are going to study how we start the control process, with high efficient control (type I) and with
minimum value (type II). Figure 2 shows the profiles of the resistance controls \( (u_{11}(t), u_{12}(t), u_{13}(t)) \) over time
for the different strategies and control types.

**Strategy I.** In this strategy all controls are active \( (u_0(t) > 0, u_{11}(t) > 0, u_{12}(t) > 0 \) and \( u_{13}(t) > 0) \).
In other words, reinfection or reactivation and resistance are controlled. We show the behavior of the controls
over time, see Figure 2a for control type I and see Figure 2b for control type II. It is observed that when this
control strategy is implemented, there is a significant decrease in the number of TB resistant compared with
the model without control, see Figure 3. In the case of MDR-TB in the different sub-populations before the
study year, a decrease in the number of reported cases was observed, see Figures 3a-3c. In the case of XR-TB,
the reduction in the number of cases will occur over a longer period of time, but this reduction is significant,
mainly in XDR-TB diabetics, which has a strong incidence in the dynamics, see Figure 3d-3f. In the case of
MDR-TB and XDR-TB in the TB-HIV/AIDS sub-population, the control manages to avoid the growth of the
number of cases because in the dynamics these compartments tend to decrease initially and then grow. This
strategy takes advantage of the decrease in the number of cases by preventing future growth. The type I control
showed better results so it is recommended to start with higher efficacy and this evokes showing better results.

**Strategy II.** Here we activate the controls \( u_0(t) > 0, u_{11}(t) > 0 \) and \( u_{12}(t) > 0 \) and \( u_{13}(t) = 0 \), this means
that we control resistance in the TB-HIV/AIDS and TB-Only sub-populations and reinfection or reactivation
TB in the full model. The behavior of the controls is shown in Figure 2c-2d.
Table 2. Values of variables and parameters used in the model (1).

| Variables       | Value   | Variables       | Value   | Variables       | Value   |
|-----------------|---------|-----------------|---------|-----------------|---------|
| $S_T(0)$        | 8741400 | $S_H(0)$        | 111000  | $S_D(0)$        | 200000  |
| $E_T(0)$        | 565600  | $E_H(0)$        | 5000    | $E_D(0)$        | 8500    |
| $I_T(0)$        | 20000   | $I_H(0)$        | 1400    | $I_D(0)$        | 1800    |
| $I_T(0)$        | 1300    | $I_H(0)$        | 400     | $I_D(0)$        | 550     |
| $R_T(0)$        | 700     | $R_H(0)$        | 210     | $R_D(0)$        | 250     |
| $R_T(0)$        | 8800    | $R_H(0)$        | 500     | $R_D(0)$        | 300     |

| Parameters      | Value               | Parameters      | Value               | Reference |
|-----------------|---------------------|-----------------|---------------------|-----------|
| $M_1$, $M_2$, $M_3$ | 667685, 10000, 50000 | $a^*$           | 9.5                 | [31–33]   |
| $a_1$, $a_2$    | 0.0075, 0.009        | $\omega_1$, $\omega_2$ | 1.22, 1.10         | [31,32,34], assumed |
| $a_4$           | 17.3 (per thousand people per year) | $\rho_1$, $\rho_2$ | 0.5, 0.4          | [31,32]   |
| $\mu_1$, $\mu_2$, $\mu_3$ | 1/53.5, 0.045, 0.03 | $\eta_1$, $\eta_2$ | 1.3, 1.1          | [31,32,34] |
| $d_1$, $d_2$, $d_3$ | 0.275, 0.33, 1.5 * $d_1$ | $\epsilon_1$, $\epsilon_2$ | 1.3, 1.1          | [34], assumed |
| $\beta_1$      | 0.9                 | $t_1$, $t_2$, $t_3$ | 1, 1.01, 1         | Assumed |
| $\mu_1$, $\mu_2$, $\mu_3$ | 0.6266, 0.45, 0.4054 | $\eta_1$, $\eta_2$, $\eta_3$ | 0.013, 0.022, 0.006 | [33,38–40], Assumed |
| $\eta_1$, $\eta_2$, $\eta_3$ | 0.7372, 0.33, 0.7372 | $p_1$, $p_2$, $p_3$ | 0.00225, 0.0035, 0.0041 | [36,37,41], Assumed |
| $\eta_1$, $\eta_2$, $\eta_3$ | 0.4006, 0.255, 0.3317 | $t_1$, $t_2$, $t_3$ | 1.01, 1.01, 1.01  | Assumed |
This strategy succeeds in reducing the number of resistant cases, but this reduction is lower than that of strategy I. It is important to keep in mind that the largest number of resistant cases are XDR-TB diabetics and this strategy reduces this compartment but not sufficiently. It is recommended to maintain control over diabetic resistant compartments, due to their impact on resistance dynamics, mainly of XR-TB. In XDR-TB, TB-HIV/AIDS and TB-Diabetes sub-populations the controls decreased the number of cases but did not take advantage of the decrease in the number of cases and with the controls, the asymptotic behavior was maintained. The type I control was more effective.

**Strategy III.** This strategy does not control resistance in the TB-Only sub-population. As in the previous strategies, the objective of reducing resistance in the dynamics is met. Controls in XDR-TB HIV/AIDS and diabetes reduced the number of cases and asymptotic behavior was maintained, but the results were better than strategy II for the different types of controls. This strategy also failed to take advantage of the decrease in the number of cases, reducing the number of cases but not avoiding future asymptotic growth, see Figures 5a, 5e and 5f. Here too, type I controls achieved better results.

In general, all strategies and types of controls met the objective of reducing the number of cases of MDR-TB and XDR-TB. The most efficient strategy was the strategy I with type I control. In addition to significantly reducing the number of cases in all resistance compartments and also takes advantage of the decrease in dynamics and prevents the future growth of cases. In all strategies, type I control showed better results, so it is recommended to start with low control. In [25] the numerical results show the need to reduce XDR-TB in diabetics due to the growth that occurs in this sub-population, so strategy II does not meet significantly this objective. Strategy II is not recommended because it fails to significantly reduce resistance in diabetics and diabetes is a risk factor for adherence to TB treatment.

5. Conclusions

In this work, we have studied the problem of control in patients to achieve greater adherence to treatment taking into account the influence of HIV/AIDS and diabetes and thus avoid MDR-TB and XDR-TB. We present the stability at the disease-free equilibrium point related to the basic reproduction number for the sub-models and proved the global stability of this point for the full model (1). The controls are defined as $u_0$, $u_1$, $u_2$ and $u_3$ and are based on avoiding reinfection or reactivation of the bacteria and on differentiated care and follow-up in cases who are neither HIV+ nor diabetics, HIV/AIDS, and diabetics. The optimal control theory for the model is derived analytically by applying Pontryagin’s maximum principle and we demonstrate the existence of optimal control. For the computational simulations, we used a fourth-order Runge-Kutta forward/backward scheme. We experimented in different scenarios built with different combinations of the controls. We present the results of the resistance compartments ($I_{T2}$, $I_{H2}$, $I_{D2}$, $R_{T1}$, $R_{H1}$ and $R_{D1}$). We concluded that all variants of strategies with the different types of controls met the objective of reducing the number of resistant cases. The strategy that obtained the best results was the strategy I (activating all controls) with type I controls (starting with the highest controls). Recommend keeping all sub-populations under control and starting with maximum control. However, if we have to use only three control, we recommended using strategy III, because all the resistance compartments and mainly the diabetic XDR-TB are reduced compared with strategy II. We do not recommend the use of strategy II, since one of the main factors of resistance to TB treatment is diabetes and this strategy did not manage to reduce significantly the number of resistant cases to TB treatment in diabetics. The results of this work help those responsible for health systems to make decisions for the efficacy of tuberculosis treatment, taking into account the influence of HIV/AIDS and diabetes. In future works, we propose to experiment in a real scenario and use differential inclusions for the control system.
Figure 2. The profiles of the controls associated with resistance in the different strategies and for the different types of controls.
(a) MDR-TB cases in the TB-Only, study period 10 years.

(b) MDR-TB cases in the TB-HIV/AIDS, study period 10 years.

(c) MDR-TB cases in the TB-Diabetes, study period 10 years.

(d) XDR-TB cases in the TB-Only, study period 10 years.

(e) XDR-TB cases in the TB-HIV/AIDS, study period 10 years.

(f) XDR-TB cases in the TB-Diabetes, study period 10 years.

Figure 3. Comparison in the resistance compartments between the types of controls for strategy I.
(a) MDR-TB cases in the TB-Only, study period 10 years.

(b) MDR-TB cases in the TB-HIV/AIDS, study period 10 years.

(c) MDR-TB cases in the TB-Diabetes sub-population, study period 10 years.

(d) XDR-TB cases in the TB-Only sub-population, study period 10 years.

(e) XDR-TB cases in the TB-HIV/AIDS sub-population, study period 10 years.

(f) XDR-TB cases in the TB-Diabetes sub-population, study period 10 years.

Figure 4. Comparison in the resistance compartments between the types of controls for strategy II.
Figure 5. Comparison in the resistance compartments between the types of controls for strategy III.

Author Contributions: All authors contributed equally in this paper. All authors read and approved final version of this paper.

Conflicts of Interest: The author declares no conflict of interest.

Data Availability: All data required for this research is included within this paper.

Funding Information: No funding is available for this research.
References

[1] Delogu, G., Sali, M., & Fadda, G. (2013). The biology of mycobacterium tuberculosis infection. Mediterranean Journal of Hematology and Infectious Diseases, 5(1), Article ID: e2013070. https://doi.org/10.4084/mjhid.2013.070.

[2] World Health Organization (WHO). Global Tuberculosis Report. (2017). https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf?ua=1. Accessed on 10 January 2019.

[3] World Health Organization (WHO). (2006). Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Weekly Epidemiological Record–Relevé Épidémiologique Hebdomadaire, 81(45), 430-432.

[4] Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Laloo, U., ... & Friedland, G. (2006). Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet, 368(9547), 1575-1580.

[5] Niazi, A. K., & Kalra, S. (2012). Diabetes and tuberculosis: a review of the role of optimal glycemic control. Journal of Diabetes & Metabolic Disorders, 11, Article No 28. https://doi.org/10.1186/2251-6581-11-28.

[6] Stevenson, C. R., Critchley, J. A., Foroughi, N. G., Roglic, G., Williams, B. G., Dye, C., & Unwin, N. C. (2007). Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illness, 3(3), 228-245.

[7] Jeon, C. Y., & Murray, M. B. (2008). Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med., 5(7), Article ID: e152. https://doi.org/10.1371/journal.pmed.0050152.

[8] Baghaei, P., Marjani, M., Javanmard, P., Tabarsi, P., & Masjedi, M. R. (2013). Diabetes mellitus and tuberculosis facts and controversies. Journal of Diabetes & Metabolic Disorders, 12, Article No 58. https://doi.org/10.1186/2251-6581-12-58.

[9] Basoglu, O. K., Bacakoglu, F., Cok, G., Saymer, A., & Ates, M. (1999). The oral glucose tolerance test in patients with respiratory infections. Monaldi Archives for Chest Disease, 54, 307-310.

[10] Mathema, B., Kurepina, N. E., Bifani, P. J., & Kreiswirth, B. N. (2006). Molecular epidemiology of tuberculosis: current insights. Clinical Microbiology Reviews, 19(4), 658-685.

[11] McVor, A., Koornhof, H., & Kana, B. D. (2017). Relapse, re-infection and mixed infections in tuberculosis disease. Pathogens and Disease, 75(3), Article ID: ftx020. https://doi.org/10.1093/femspd/ftx020.

[12] Kim, S., Aurelio, A., & Jung, E. (2018). Mathematical model and intervention strategies for mitigating tuberculosis in the Philippines. Journal of Theoretical Biology, 443, 100-112.

[13] Silva, C. J., & Torres, D. F. (2013). Optimal control for a tuberculosis model with reinfection and post-exposure interventions. Mathematical Biosciences, 244(2), 154-164.

[14] Jung, E., Lenhart, S., & Feng, Z. (2002). Optimal control of treatments in a two-strain tuberculosis model. Discrete & Continuous Dynamical Systems-B, 2(4), 473-482.

[15] Silva, C. J., Maurer, H., & Torres, D. F. M. (2017). Optimal control of a tuberculosis model with state and control delays. Mathematical Biosciences and Engineering, 14(2): 321-327.

[16] Silva, C. J., & Torres, D. F. (2013). Optimal control for a tuberculosis model with reinfection and post-exposure interventions. Mathematical Biosciences, 244(2), 154-164.

[17] Tahir, M., Shah, S. I. A., & Zaman, G. (2017). Prevention strategy for superinfection mathematical model tuberculosis and HIV associated with AIDS. Cogent Mathematics & Statistics, 6(1), Article ID: 1637166. https://doi.org/10.1080/25742558.2019.1637166.

[18] Awoke, T. D., & Kassa, S. M. (2018). Optimal control strategy for TB-HIV/AIDS Co-Infection Model in the Presence of Behaviour Modification. Processes, 6(5), 48-73.

[19] Augusto, F. B., & Adekunle, A. I. (2014). Optimal control of a two-strain tuberculosis-HIV/AIDS coinfection model. Biosystems, 119, 20-44.

[20] Silva, C. J., & Torres, D. F. M. (2015). A TB-HIV/AIDS co-infection model and optimal control treatment. Discrete & Continuous Dynamical System Serie B, 35(9), 4639-4663.

[21] Fatmawati & Tasman, H. (2016). An Optimal Treatment Control of TB-HIV Co-infection. International Journal of Mathematics and Mathematical Sciences, 2016, Article ID 8261208. https://doi.org/10.1155/2016/8261208.

[22] Tanvi, R. Aggarwal. (2020). Optimal Control Analysis of HIV-TB Co-infection Model. In: Mondaini R. (eds) Trends in Biomathematics: Modeling Cells, Flows, Epidemics, and the Environment. BIOMAT 2019. Springer, Cham. https://doi.org/10.1007/978-3-030-46306-9_17.

[23] Kouidere, A., Labzai, A., Ferjouchia, H., Balatif, O., & Rachik, M. (2020). A new mathematical modeling with optimal interventions. Mathematical Biosciences, 244(2), 154-164.

[24] Chávez, I. Y. S., Morales-Menéndez, R., & Chapa, S. O. M. (2009). Glucose optimal control system in diabetes treatment. Applied Mathematics and Computation, 209, 19–30.

[25] Moya, E. D., Pietrus, A., & Oliva, S. M. (2021). A mathematical model for the study of effectiveness in therapy in Tuberculosis taking into account associated diseases. Contemporary Mathematics, 2, 77-102.

[26] Driessche, P. V., & Watmough, J. (2002). Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical Biosciences, 180(1-2), 29-48.
[27] Castillo-Chavez, C., Feng, Z., & Huang, W. (2002). On the computation of $\mathcal{R}_0$ and its role on global stability. In: *Mathematical Approaches for Emerging and Reemerging Infectious Diseases: An Introduction*, Springer-Verlag, New York, 229-250.

[28] Fleming, W. H., & Rishel, R. W. (1975). *Deterministic and Stochastic Optimal Control*. Springer Verlag New York.

[29] Pontryagin, L., Boltyanskij, V., Gamkrelvdze, R. & Mishchenko, E. (1962). *The Mathematical Theory of Optimal Processes*. Jonh Wiley and Sons, New Yor, NY, USA.

[30] Lenhart, S., & Workman, J. T. (2007). *Optimal Control Applied to Biological Models*. Chapman and Hall, Boca Raton.

[31] Carvalho, A. R., & Pinto, C. M. (2018). Non-integer order analysis of the impact of diabetes and resistant strains in a model for TB infection. *Communications in Nonlinear Science and Numerical Simulation*, 61, 104-126.

[32] Moualeu, D. O., Bowong, S., Tewa, J. J., & Emviedu, Y. (2011). Analysis of the impact of diabetes on the dynamical transmission of tuberculosis. *Mathematical Modelling of Natural Phenomena*, 7(3), 117-146.

[33] Agusto, F. B., Cook, J., Shelton, P. D., & Wickers, M. G. (2015). Mathematical model of MDR-TB and XDR-TB with isolation and lost to follow-up. *Abstract and Applied Analysis*, 2015, Article ID 828461. https://doi.org/10.1155/2015/828461.

[34] Silva, C., & Torres, D. F. M. (2015). A TB-HIV/AIDS co-infection model and optimal control treatment. *Discrete & Continuous Dynamical Systems*, 35(9), 4639-4663.

[35] Cassetone, A. J. F. Advisor: Segurado, A. A. C., & co-advisor: Abe, J. M. (2019). Alterações metabólicas associadas ao uso de medicamento antirretroviral em pessoas vivendo com HIV/AIDS: caracterização e desenvolvimento de algoritmos inteligentes aplicados à sua identificação e previsão. *Tese de Doutorado*, USP. https://doi.org/10.11606/T.5.2017.tde-14122017-112914.

[36] Castillo-Chavez, C., & Feng, Z. (1997). To treat or not to treat: The case of tuberculosis. *Journal of Mathematical Biology*, 35(6), 629-56.

[37] Jung, E., Lenhart, S., & Feng, Z. (2002). Optimal control of treatments in a two-strain tuberculosis model. *Discrete & Continuous Dynamical Systems-B*, 2(4), 473-482.

[38] Hickson, R. I., Mercer, G. N., & Lokuge, K. M. (2012). A metapopulation model of tuberculosis transmission with a case study from high to low burden areas. *PLoS One*, 7(4), Article ID: e34411. https://doi.org/10.1371/journal.pone.0034411.

[39] Blower, S. M., Mclean, A. R., Porco, T. C., Small, P. M., Hopewell, P. C., Sanchez, M. A., & Moss, A. R. (1995). The intrinsic transmission dynamics of tuberculosis epidemics. *Nature Medicine*, 1(8), 815-821.

[40] Cohen, T., Colijn, C., Finklea, B., & Murray, M. (2007). Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. *Journal of the Royal Society Interface*, 4(14), 523-531.

[41] Liu, Y., Sun, Z., Sun, G., Zhong, Q., Jiang, L., Zhou, L., ... & Jia, Z. (2011). Modeling transmission of tuberculosis with MDR and undetected cases. *Discrete Dynamics in Nature and Society*, 2011, Article ID: 296905. https://doi.org/10.1155/2011/296905.

© 2022 by the authors; licensee PSRP, Lahore, Pakistan. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).